Signal Transduction and Targeted Therapy (Mar 2022)

ACE2-independent infection of T lymphocytes by SARS-CoV-2

  • Xu-Rui Shen,
  • Rong Geng,
  • Qian Li,
  • Ying Chen,
  • Shu-Fen Li,
  • Qi Wang,
  • Juan Min,
  • Yong Yang,
  • Bei Li,
  • Ren-Di Jiang,
  • Xi Wang,
  • Xiao-Shuang Zheng,
  • Yan Zhu,
  • Jing-Kun Jia,
  • Xing-Lou Yang,
  • Mei-Qin Liu,
  • Qian-Chun Gong,
  • Yu-Lan Zhang,
  • Zhen-Qiong Guan,
  • Hui-Ling Li,
  • Zhen-Hua Zheng,
  • Zheng-Li Shi,
  • Hui-Lan Zhang,
  • Ke Peng,
  • Peng Zhou

DOI
https://doi.org/10.1038/s41392-022-00919-x
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 11

Abstract

Read online

Abstract SARS-CoV-2 induced marked lymphopenia in severe patients with COVID-19. However, whether lymphocytes are targets of viral infection is yet to be determined, although SARS-CoV-2 RNA or antigen has been identified in T cells from patients. Here, we confirmed that SARS-CoV-2 viral antigen could be detected in patient peripheral blood cells (PBCs) or postmortem lung T cells, and the infectious virus could also be detected from viral antigen-positive PBCs. We next prove that SARS-CoV-2 infects T lymphocytes, preferably activated CD4 + T cells in vitro. Upon infection, viral RNA, subgenomic RNA, viral protein or viral particle can be detected in the T cells. Furthermore, we show that the infection is spike-ACE2/TMPRSS2-independent through using ACE2 knockdown or receptor blocking experiments. Next, we demonstrate that viral antigen-positive T cells from patient undergone pronounced apoptosis. In vitro infection of T cells induced cell death that is likely in mitochondria ROS-HIF-1a-dependent pathways. Finally, we demonstrated that LFA-1, the protein exclusively expresses in multiple leukocytes, is more likely the entry molecule that mediated SARS-CoV-2 infection in T cells, compared to a list of other known receptors. Collectively, this work confirmed a SARS-CoV-2 infection of T cells, in a spike-ACE2-independent manner, which shed novel insights into the underlying mechanisms of SARS-CoV-2-induced lymphopenia in COVID-19 patients.